Phase 1b Randomized Study of Antidote-Controlled Modulation of Factor IXa Activity in Patients With Stable Coronary Artery DiseaseMark Y. Chan, Christopher P. Rusconi, Laura G. Aberle et al.|Circulation|2008Cited by 130
First Clinical Application of an Actively Reversible Direct Factor IXa Inhibitor as an Anticoagulation Strategy in Patients Undergoing Percutaneous Coronary InterventionMauricio G. Cohen, Richard C. Becker, Drew A. Purdy et al.|Circulation|2010Cited by 98